Objective: To observe bevacizumab plus chemotherapy curative effect and safety for recurrent and metastatic cervical cancer. Materials and Methods: Retrospective analysis of 30 recurrent and metastatic cervical cancer cases. The experimental group received bevacizumab plus paclitaxel-, docetaxel-, and platinum-based chemotherapy. The control group received only chemotherapy. Curative effects were recorded after at least two treatment cycles; adverse reactions were recorded with every cycle. Results: Experimental group patients were treated for an average 2.6 cycles. Compared to the control group, the experimental group effective rate (26.7%) was similar, disease control rate (73.7%) was significantly higher, and median survival time was three months longer. Bevacizumab-associated adverse reactions were bleeding, hypertension, and thrombosis/embolism; most were level 1 and 2 reactions. Adverse reactions in the two groups were not statistically different. Conclusions: The bevacizumab plus chemotherapy disease control rate for recurrent and metastatic cervical cancer is comparatively high, prolonging median survival; bevacizumab-associated adverse reactions are mild and tolerable.